Pfizer Independent Medical Education Grant Request for Proposals: Current and Emerging Therapies for Recurrent or Metastatic Cervical Cancer
Pfizer funds educational projects to advance clinician knowledge and care for recurrent or metastatic cervical cancer, focusing on new therapies, adverse event management, and long-term outcomes.
Funder: Pfizer Inc.
Due Dates: September 1, 2026: Submission Deadline (full application)
Funding Amounts: Typical project awards range from $50,000–$250,000 for up to 1 year; total available budget is $250,000.
Summary: Supports independent continuing education projects to advance clinician knowledge and care for recurrent or metastatic cervical cancer, with a focus on new therapies and treatment strategies.
Key Information: Only organizations (not individuals) may apply; U.S.-based projects only; no clinical research supported.
Description
This opportunity from Pfizer Inc. funds independent medical education projects aimed at improving the knowledge, competence, and confidence of clinicians and care teams managing patients with recurrent or metastatic (r/m) cervical cancer. The grant focuses on educational needs related to evolving treatment paradigms, targeted therapies (including post-immuno-oncology progression and antibody-drug conjugates), adverse event management, and long-term patient outcomes. Projects should target community oncology settings and may utilize diverse educational formats, such as live sessions, workshops, digital toolkits, and enduring online materials. Clinical research or projects evaluating the efficacy of therapeutic or diagnostic agents are not eligible.
